Breaking: Eiger Biopharmaceuticals (EIGR) “Buy” Rating Kept at Piper Jaffray Today; The Target is $28.0000

May 18, 2018 - By reb123z

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Eiger Biopharmaceuticals (EIGR) Rating Reaffirmed

Piper Jaffray now has a $28.0000 target price on shares of Eiger Biopharmaceuticals (EIGR). The target price gives a potential upside of 66.67 % from the last stock price of Eiger Biopharmaceuticals (EIGR). This rating was disclosed to clients in a research report on 18 May.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Coverage

Among 6 analysts covering Eiger Biopharmaceuticals (EIGR), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eiger Biopharmaceuticals has $5300 highest and $17.0 lowest target. $30.83’s average target is 83.51% above currents $16.8 stock price. Eiger Biopharmaceuticals had 13 analyst reports since December 19, 2017 according to SRatingsIntel. The rating was maintained by BTIG Research on Thursday, May 17 with “Buy”. The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has “Buy” rating given on Wednesday, April 18 by Wedbush. The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has “Buy” rating given on Tuesday, January 16 by Piper Jaffray. The company was maintained on Friday, January 5 by Wedbush. On Monday, March 12 the stock rating was maintained by Oppenheimer with “Buy”. The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) earned “Buy” rating by Wedbush on Thursday, May 17. On Friday, May 11 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Jefferies on Tuesday, January 16 with “Buy”. The stock has “Buy” rating by Piper Jaffray on Wednesday, March 21. The rating was maintained by Wedbush on Tuesday, December 19 with “Buy”.

The stock increased 41.77% or $4.95 during the last trading session, reaching $16.8. About 1.29 million shares traded or 1251.65% up from the average. Eiger BioPharmaceuticals, Inc. (EIGR) has declined 11.57% since May 18, 2017 and is downtrending. It has underperformed by 23.12% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.98 earnings per share, up 26.32 % or $0.35 from last year’s $-1.33 per share. After $-0.84 actual earnings per share reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $177.07 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

More notable recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: 247Wallst.com which released: “Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 …” on May 17, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” published on May 18, 2018, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For May 9, 2018” on May 09, 2018. More interesting news about Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) were released by: Streetinsider.com and their article: “After-Hours Stock Movers 05/17: (QTNT) (VJET) (AFSI) Higher; (ARQL) (JWN) (AMAT) Lower (more…)” published on May 17, 2018 as well as Benzinga.com‘s news article titled: “24 Stocks Moving In Friday’s Pre-Market Session” with publication date: May 18, 2018.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.